Ipsen — Capital/Financing Update 2025

Jan 7, 2025

Half-year statement of IPSEN liquidity agreement with NATIXIS ODDO BHF

Boulogne-Billancourt (France), January 7 th, 2025 – Under the liquidity agreement entrusted by IPSEN SA to NATIXIS ODDO BHF, as of December 31, 2024, the following resources were included to the dedicated liquidity account:

• 24,701 shares
• €2,635,980.25

It is reminded that as of the date of the implementation of the agreement, the following resources were allocated to the liquidity account:

• 12,751 shares
• €3,137,934.80

Between July 1st, 2024 and December 31 st, 2024 have been executed:

• 2,936 purchase transactions
• 2,346 sell transactions

Under the same period, the volumes traded represented:

• 311,792 shares and €33,997,824.80 to the purchase
• 321,682 shares and €35,215,771.10 to the sell

About Ipsen

Ipsen is a global biopharmaceutical company with a focus on bringing transformative medicines to patients in three therapeutic areas: Oncology, Rare Disease and Neuroscience.

Our pipeline is fuelled by external innovation and supported by nearly 100 years of development experience and global hubs in the U.S., France and the U.K. Our teams in more than 40 countries and our partnerships around the world enable us to bring medicines to patients in more than 100 countries.

Ipsen is listed in Paris (Euronext: IPN) and in the U.S. through a Sponsored Level I American Depositary Receipt program (ADR: IPSEY). For more information, visit ipsen.com.

Ipsen contacts

Investors

Alina Levchuk +41 79 572 8712 Nicolas Bogler +33 6 52 19 98 92

Media

Jennifer Smith-Parker +44(0) 7843 137 764 Anne Liontas +33 7 67 34 72 96